BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Inaba H, Panetta JC, Pounds SB, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz JE, Baker SD. Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clin Cancer Res 2019;25:7320-30. [PMID: 31455680 DOI: 10.1158/1078-0432.CCR-19-0470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Linggonegoro DW, Song H, Huang JT. Supportive Oncodermatology in Pediatric Patients. Dermatologic Clinics 2022. [DOI: 10.1016/j.det.2021.12.007] [Reference Citation Analysis]
2 Noda S, Morita SY, Terada T. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring. Biol Pharm Bull 2022;45:814-23. [PMID: 35786588 DOI: 10.1248/bpb.b21-01098] [Reference Citation Analysis]
3 Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, Eisenmann ED, Gibson AA, Oomen-de Hoop E, de Bruijn P, Baker SD, Koolen SLW, van Gelder T, van Leeuwen RWF, Mathijssen RHJ, Sparreboom A, Bins S. Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. Pharmaceutics 2020;12:E788. [PMID: 32825359 DOI: 10.3390/pharmaceutics12090788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Eisenmann ED, Garrison DA, Talebi Z, Jin Y, Silvaroli JA, Kim J, Sparreboom A, Savona MR, Mims AS, Baker SD. Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination. Pharmaceutics 2022;14:694. [DOI: 10.3390/pharmaceutics14040694] [Reference Citation Analysis]
5 Federico SM, Caldwell KJ, McCarville MB, Daryani VM, Stewart CF, Mao S, Wu J, Davidoff AM, Santana VM, Furman WL, Pappo AS, Navid F. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours. Eur J Cancer 2020;132:35-42. [PMID: 32325418 DOI: 10.1016/j.ejca.2020.03.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Booth L, Poklepovic A, Dent P. Not the comfy chair! Cancer drugs that act against multiple active sites. Expert Opin Ther Targets 2019;23:893-901. [PMID: 31709855 DOI: 10.1080/14728222.2019.1691526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
7 Hasan Alshammari A, Masuo Y, Fujita KI, Shimada K, Iida N, Wakayama T, Kato Y. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition. Biochem Pharmacol 2022;:114914. [PMID: 35041812 DOI: 10.1016/j.bcp.2022.114914] [Reference Citation Analysis]
8 Sparber-Sauer M, Orbach D, Navid F, Hettmer S, Skapek S, Corradini N, Casanova M, Weiss A, Schwab M, Ferrari A. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis. Br J Cancer 2021;124:1637-46. [PMID: 33723397 DOI: 10.1038/s41416-021-01320-1] [Reference Citation Analysis]